AXIM Biotechnologies (OTCMKTS:AXIM) versus Adial Pharmaceuticals (NASDAQ:ADIL) Financial Comparison

Adial Pharmaceuticals (NASDAQ:ADIL) and AXIM Biotechnologies (OTCMKTS:AXIM) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Profitability

This table compares Adial Pharmaceuticals and AXIM Biotechnologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adial Pharmaceuticals	N/A	-197.73%	-153.71%
AXIM Biotechnologies	N/A	N/A	N/A

Analyst Recommendations

This is a summary of recent recommendations and price targets for Adial Pharmaceuticals and AXIM Biotechnologies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adial Pharmaceuticals	1	1	1	0	2.00
AXIM Biotechnologies	0	0	0	0	0.00

Adial Pharmaceuticals presently has a consensus target price of $1.50, suggesting a potential upside of 548.23%. Given Adial Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts plainly believe Adial Pharmaceuticals is more favorable than AXIM Biotechnologies.

Institutional and Insider Ownership

16.4% of Adial Pharmaceuticals shares are held by institutional investors. 4.3% of Adial Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Adial Pharmaceuticals and AXIM Biotechnologies”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adial Pharmaceuticals	N/A	N/A	-$13.20 million	($0.75)	-0.31
AXIM Biotechnologies	N/A	N/A	N/A	($0.01)	-1.52

AXIM Biotechnologies is trading at a lower price-to-earnings ratio than Adial Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Adial Pharmaceuticals beats AXIM Biotechnologies on 6 of the 9 factors compared between the two stocks.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.

About AXIM Biotechnologies

AXIM Biotechnologies, Inc. engages in the development and sale of diagnostic healthcare solutions in the areas of SARS-CoV-2, eye health, and other diseases. The company is developing tests for dye eye diseases; SARS-CoV-2 neutralizing antibody tests; and fentanyl neutralizing antibody tests. It also developing a line of novel diagnostics for early cancer detection, response to treatment, and recurrence monitoring. The company was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014. AXIM Biotechnologies, Inc. was incorporated in 2010 and is based in San Diego, California.